Jeroen Dekervel, MD, PhD, KU Leuven, Leuven, Belgium, provides an overview of treatment options for patients with rectal cancer. A vast majority of patients have microsatellite stable (MSS) rectal cancer, as opposed to high microsatellite instability (MSI-H) rectal cancer, resulting in immunotherapy and targeted therapies having limited efficacy in this indication. Chemotherapy is, therefore, the main course of treatment for most patients. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
